One of the many challenges associated with Alzheimer’s disease (AD) is timely identification and diagnosis – the earlier the disease can be caught, the higher the potential to prevent, or slow down, its progression with interventions like brain training or nootropic drugs. Retinal exams might be the answer, and already multiple research groups are investigating their diagnostic potential: a team from the University of Minnesota are evaluating retinal non-invasive hyperspectral endoscopy to look for signs of amyloidopathy in a mouse model of AD (1), and another group at the University of Waterloo in Ontario have shown that ß-amyloid deposits in neural retina can be detected non-invasively using their polarized light microscopes (2). But this isn’t the whole story: results from a large cohort study (3) have shown that retinal nerve fiber layer (RNFL) thinning is significantly associated with poor cognitive function, which immediately suggests that regular retinal thickness measurements could represent an important method of catching early signs of the disease.
Enjoy our FREE content!
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
If you don’t have an account you can:
REGISTER NOW – it’s FREE and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
Or Login as a Guest or via Social Media
This will allow you to read this article but you will only have limited access to The Ophthalmologist.Login as Guest Twitter LinkedIn Google+ Facebook